Par Pharmaceutical Companies Inc.
http://www.parpharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Par Pharmaceutical Companies Inc.
CEO Sets Strides For Growth With Endo Execs
Appointing executives from Endo in key positions, Strides' CEO has set up a team to deliver growth, though the impact of ranitidine withdrawal and COVID-19 will defer a revenue target of $800m. Meanwhile, Stelis Biopharma signals a shift in focus from biologics development to CDMO opportunities and is poised for a stock exchange listing.
CEO Sets Strides For Growth With Endo Execs
Appointing executives from Endo in key positions, Strides' CEO has set up a team to deliver growth, though the impact of ranitidine withdrawal and COVID-19 will defer a revenue target of $800m. Meanwhile, Stelis Biopharma signals a shift in focus from biologics development to CDMO opportunities and is poised for a stock exchange listing.
Who’s Hired? IGBA Names IPA’s Jain As Chair
The International Generic and Biosimilar Medicines Association has named the IPA’s Sudarshan Jain as its new chair. While Celltrion’s chairman has stepped down, Coherus has added two members to its board of directors and Synthon has appointed a new CEO.
Pfizer Faces 15-Year Wait On US Adrenalin Generic
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
Company Information
- Other Names / Subsidiaries
-
- Anchen Pharmaceuticals, Inc.
- Edict Pharmaceuticals Private Limited
- JHP Pharmaceuticals, LLC
- Strativa Pharmaceuticals
- TPG Capital LP